Credit: Riccardo Di Corato – laboratoire MSC (CNRS/Université Paris Diderot)
By combining, in a liposome, magnetic nanoparticles and photosensitizers that are simultaneously and remotely activated by external physical stimuli (a magnetic field and light), scientists obtained total tumor regression in mice.
Non-toxic when they are not activated, such therapies can also achieve a reduction in adverse effects. These results demonstrate the importance of multiple treatments.
One of the strategies employed to limit the adverse effects of cancer therapies is the development of nanocarrier systems that can convey active ingredients to target tumor cells. These are referred to as “physical” therapies when the active substances, molecules or nanoparticles, can be remotely activated by external physical stimuli — in this case by light or a magnetic field. In this context, the study team developed a new type of carrier that combines photosensitivity and magnetism. To achieve this, they first encapsulated magnetic nanoparticles in the inner compartment of a liposome in sufficient quantities to render it ultra-magnetic, before incorporating photosensitizers into its lipid bilayer, while preserving an optimum size for circulation in the blood.
These liposomes, containing magnetic nanoparticles and photosensitizers, were injected directly into the tumor in the mouse model. The scientists thus combined two techniques to achieve complete destruction of cancer cells. The first one, magnetic hyperthermia, consists in exciting the nanoparticles with a magnetic field to raise the temperature of the tumor and destroy it.. The second method, photodynamic therapy, is made possible by the photosensitizers, which, when activated, release reactive oxygen species that are toxic to tumor cells. These two physical therapies act in synergy on the activity of the proteins involved in apoptosis, or programmed cell death. Their combination thus induces total regression of the tumor, while a single therapy is not able to stop its growth.
Read more: Combining magnetism and light to fight cancer
The Latest on: Tumor regression
[google_news title=”” keyword=”Tumor regression” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Tumor regression
- THIO-Libtayo Regimen Is ‘Encouraging’ for Relapsed NSCLCon July 25, 2024 at 8:00 am
Sequencing the novel drug, THIO, with Libtayo tended to be tolerable in patients with non-small cell lung cancer, recent research showed.
- Par-4 Protein's Role in Inducing Unique Cell Death in Cancer Cells Uncoveredon July 24, 2024 at 7:37 pm
Researchers have discovered that the tumor suppressor protein Par-4 induces a unique cell death pathway known as ferroptosis in cancerous cells, leaving healthy cells unharmed.
- OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Canceron July 24, 2024 at 3:48 am
HER2-targeted antibody alone Tg tumor regression model of breast cancer at day 42 65% reduction cellular concentration of metastatic cells for OST-HER2-treated mice compared with controls in brain ...
- Tumor Suppressor Protein Triggers Unique Death Pathway in Cancer Cellson July 23, 2024 at 5:00 pm
the researchers identified that Par-4 plays an unanticipated role in promoting ferroptosis-mediated cancer regression. They demonstrated that Par-4 triggers the activation of ferritinophagy ...
- Tumor suppressor protein Par-4 triggers unique cell death pathway in cancerous cellson July 23, 2024 at 11:51 am
A team of researchers has discovered that the tumor suppressor protein Prostate apoptosis response-4 (Par-4) can cause a unique type of cell death called ferroptosis in human glioblastoma -- the most ...
- Tumor suppressor protein Par-4 found to trigger unique cell death pathway in cancer cellson July 23, 2024 at 9:58 am
A team of researchers at NYU Abu Dhabi, led by Professor Sehamuddin Galadari, has discovered that the tumor suppressor protein Prostate apoptosis response-4 (Par-4) can cause a unique type of cell ...
- NYU Abu Dhabi researchers discover tumor suppressor protein Par-4 triggers unique cell death pathway in cancerous cellson July 22, 2024 at 5:00 pm
A team of researchers at NYU Abu Dhabi has discovered that the tumor suppressor protein Prostate apoptosis response-4 (Par-4) can cause a unique type of cell death called ferroptosis in human ...
- Novel Protein Found to Have Dual Function Associated with Tumor Progressionon July 18, 2024 at 7:00 am
Cancer is an adaptable disease and context dependent. More specifically, tumors can respond differently to therapies. Various therapeutic responses are associated with different factors that play a ...
- Brain Cancer Cure Soon? New Treatment Removes Tumor In Woman Within 5 Dayson July 16, 2024 at 11:51 pm
These cells called CART-TEAM were then injected back into the patients to target the tumor cells. After the treatment, a 74-year-old patient experienced tumor regression and it eventually became ...
- Immunotherapy Is Changing Cancer Treatment Foreveron July 15, 2024 at 2:01 am
One morning at the end of April 2023, Marcela Maus, a cancer researcher at Mass General in Boston, got a call from her colleague Bryan Choi. “He called me, and he’s like, ‘Oh my God, oh my God, oh my ...
via Bing News
